Inclusion Criteria:

          -  Prior diagnosis of either high-risk myelodysplastic syndrome (myelodysplastic syndrome
             [MDS]; defined as >= 10% blasts in bone marrow or blood), high-risk myeloproliferative
             neoplasms (myeloproliferative neoplasms [MPN]; defined as >= 10% blasts in bone marrow
             or blood), or AML based on 2016 World Health Organization criteria. Acute
             promyelocytic leukemia (APL) and biphenotypic AML are not eligible

          -  Patients must have MRD-level disease only and otherwise meet criteria for complete
             response (CR) or complete remission with incomplete hematologic recovery (CRi) per the
             2017 European Leukemia Net response criteria (< 5% blasts in the marrow without a
             requirement for peripheral blood count recovery). MRD must be measurable by
             multiparameter flow cytometry (MPFC) and/or polymerase chain reaction (PCR)-based
             molecular markers and/or karyotypic markers (e.g., classical cytogenetics or
             fluorescence in situ hybridization). MRD status will be centrally confirmed by the
             UW/FHCRC clinical laboratory in order to standardize response assessment following
             administration of study therapy.

          -  Patients must have received at least 1 cycle of standard induction chemotherapy prior
             to enrollment on the study. However, adult patients (>= 18 years of age) are eligible
             for participation at any time point in treatment (after induction, during or after
             consolidation, pre-transplant, or post-transplant). Pediatric patients (2-18 years of
             age) must have MRD positivity during/after consolidation or post-transplant.

          -  Age >= 2 years of age

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 3 (for adults) or
             Lansky performance status >= 40 (for children).

          -  Patient's AML blasts must have CD33 expression.

          -  For adults (>= 18 years of age): Serum creatinine =< 2.0 mg/dL.

          -  For adults (>= 18 years of age): Total bilirubin =< 2 x institutional upper limit of
             normal for age (unless known history of Gilbert's disease).

          -  For adults (>= 18 years of age): Aspartate aminotransferase (AST) and alanine
             aminotransferase (ALT) < 2.5 x institutional upper limit of normal for age (unless
             thought to be related to resolving infectious complications).

          -  For children (< 18 years of age): Glomerular filtration rate (GFR) in ml/min (age 2:
             63-175; age 3-12: 89-165; females 13 and older: 75-115; males 13 and older: 85-125).

          -  For children (< 18 years of age): Total bilirubin =< 2 x institutional upper limit of
             normal for age (unless known history of Gilbert's disease).

          -  For children (< 18 years of age): AST and ALT < 2.5 x institutional upper limit of
             normal for age (unless thought to be related to resolving infectious complications).

          -  Ability of patient or representative to provide written informed consent.

          -  Females of childbearing potential must have a negative pregnancy test prior to
             receiving GO.

        Exclusion Criteria:

          -  Subjects who have had chemotherapy or radiation therapy within 14 days prior to
             entering the study.

          -  Subjects may not be receiving other investigational agents.

          -  Uncontrolled or concurrent illness including, but not limited to, uncontrolled
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.